Synopsis
Synopsis
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Alpha-chymotrypsin Choay
2. Alphacutane
3. Avazyme
1. Chymotrypsin Substrate I, Colorimetric
2. 9004-07-3
3. 4-[[2-[[2-[[1-(4-nitroanilino)-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-4-oxobutanoic Acid
4. A-chymotrypsin
5. Dtxsid30988741
6. Akos024350585
7. Db-055212
8. Ft-0641215
9. N-succinyl-gly-gly-phe-p-nitroanilide, Protease Substrate
10. N-(3-carboxy-1-oxopropyl)glycylglycyl-n-(4-nitrophenyl)-l-phenylalaninamide
11. 4-hydroxy-4-({2-hydroxy-2-[(2-hydroxy-2-{[1-(4-nitroanilino)-1-oxo-3-phenylpropan-2-yl]imino}ethyl)imino]ethyl}imino)butanoic Acid
1. Alpha Chymotrypsin
Molecular Weight | 499.5 g/mol |
---|---|
Molecular Formula | C23H25N5O8 |
XLogP3 | 0.4 |
Hydrogen Bond Donor Count | 5 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 12 |
Exact Mass | 499.17031277 g/mol |
Monoisotopic Mass | 499.17031277 g/mol |
Topological Polar Surface Area | 200 Ų |
Heavy Atom Count | 36 |
Formal Charge | 0 |
Complexity | 801 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
EXPTL USE (MEDICATION (VET):): CHYMOTRYPSIN CAN BE SHOWN TO HAVE AN ANTI-INFLAMMATORY ACTION IN EXPTL ANIMALS, BUT ONLY WHEN THE ENZYME IS ADMIN PARENTERALLY IN DOSES 10 TO 20 TIMES THOSE EMPLOYED CLINICALLY & PRIOR TO THE PRODN OF THE INFLAMMATION.
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 957
...USED FOR RELIEF OF SYMPTOMS RELATED TO EPISIOTOMY. ITS USEFULNESS IN INFLAMMATORY STATES SECONDARY TO SURGICAL OR PHYSICAL TRAUMA REMAINS UNPROVEN.
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 957
ALPHA-CHYMOTRYPSIN...IS...USED IN CATARACT OPERATIONS TO LOOSEN THE LENS AFTER INCISION OF CORNEA. AFTER THE CORNEOSCLERAL OR CORNEOSCLERALCONJUNCTIVAL INCISION, THE POSTERIOR CHAMBER IS IRRIGATED WITH ABOUT 2 ML OF ENZYME SOLN (150 UNITS PER ML) TO FRAGMENT FIBERS OF THE ZONULE (ENZYMATIC ZONULOLYSIS).
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 957
...FOR DEBRIDEMENT OF NECROTIC WOUNDS, ULCERS, ABSCESSES, EMPYEMAS, & FISTULAS. IT HAS BEEN USED ALSO FOR LIQUIFACTION OF BLOOD & EXUDATES THAT HAVE NOT BECOME ORGANIZED BY FIBROUS TISSUE.
Osol, A. and J.E. Hoover, et al. (eds.). Remington's Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack Publishing Co., 1975., p. 972
For more Therapeutic Uses (Complete) data for CHYMOTRYPSIN (10 total), please visit the HSDB record page.
...IT IS NOT RECOMMENDED FOR USE IN OPHTHALMIC SURGERY IN PT UNDER 20 YEARS OF AGE BECAUSE OF POSSIBLE LOSS OF VITREOUS HUMOR.
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 957
GLAUCOMA, AS A COMPLICATION OF USE OF CHYMOTRYPSIN IN CATARACT EXTRACTIONS IN PT, HAS OCCURED USUALLY WITHIN 2 TO 5 DAYS AFTER OPERATION... THERE HAVE BEEN PRACTICALLY NO INDICATIONS OF LONGER-PERSISTING GLAUCOMA, FROM USE OF THE ENZYME.
Grant, W. M. Toxicology of the Eye. 2nd ed. Springfield, Illinois: Charles C. Thomas, 1974., p. 292
No therapeutic indications.
Chymotrypsin is a digestive enzyme synthesized in the pancreas that plays an essential role in proteolysis, or the breakdown of proteins and polypeptides. As a component in the pancreatic juice, chymotrypsin aids in the digestion of proteins in the duodenum by preferentially cleaving peptide amide bonds.
B - Blood and blood forming organs
B06 - Other hematological agents
B06A - Other hematological agents
B06AA - Enzymes
B06AA04 - Chymotrypsin
S - Sensory organs
S01 - Ophthalmologicals
S01K - Surgical aids
S01KX - Other surgical aids
S01KX01 - Chymotrypsin
Absorption
No pharmacokinetic data available.
Route of Elimination
No pharmacokinetic data available.
Volume of Distribution
No pharmacokinetic data available.
Clearance
No pharmacokinetic data available.
No pharmacokinetic data available.
No pharmacokinetic data available.
Chymotrypsin is synthesized by pancreatic acinar cells as an inactive precursor, chymotrypsinogen, that is secreted to the duodenum and activated via trypsin-induced cleavage. It also induces its own activation by cleaving essential amino acid residues in the oxyanion hole to produce -Chymotrypsin, which is a more stable form than -Chymotrypsin. Residues His-57, Asp-102, and Ser-195 form the catalytic triad while residues 189195, 214220, and 225228 form the primary substrate-binding pocket called S1 binding pocket. Residue 189 in the polar serine residue that lies at the bottom of the S1 binding pocket. Chymotrypsin favors aromatic residues like phenylalanine, tyrosine, and tryptophan but may hydrolyze other bonds in peptides at slower rates.
THEY SPLIT SECONDARY AMIDE OR PEPTIDE BONDS, CARBOXYLIC OR PHENOLIC ESTER BONDS & EVEN CARBON-CARBON BONDS. THEIR MAIN FUNCTION IS TO HYDROLYZE PEPTIDE BONDS DURING THE INTESTINAL DIGESTION OF PROTEINS. /CHYMOTRYPSINS/
The Merck Index. 9th ed. Rahway, New Jersey: Merck & Co., Inc., 1976., p. 293
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 28779
Submission : 2014-08-15
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 26454
Submission : 2012-08-30
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 31033
Submission : 2016-09-19
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 490
Submission : 1962-06-22
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 2837
Submission : 1977-01-27
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 407
Submission : 1960-11-07
Status : Inactive
Type : II
Certificate Number : R1-CEP 2003-249 - Rev 00
Issue Date : 2009-06-05
Type : TSE
Substance Number : 476
Status : Valid
Certificate Number : R1-CEP 2000-216 - Rev 03
Issue Date : 2009-02-06
Type : TSE
Substance Number : 476
Status : Valid
Certificate Number : R1-CEP 2001-209 - Rev 03
Issue Date : 2013-12-18
Type : TSE
Substance Number :
Status : Valid
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Chymotrypsin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Chymotrypsin, including repackagers and relabelers. The FDA regulates Chymotrypsin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Chymotrypsin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Chymotrypsin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Chymotrypsin supplier is an individual or a company that provides Chymotrypsin active pharmaceutical ingredient (API) or Chymotrypsin finished formulations upon request. The Chymotrypsin suppliers may include Chymotrypsin API manufacturers, exporters, distributors and traders.
click here to find a list of Chymotrypsin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Chymotrypsin DMF (Drug Master File) is a document detailing the whole manufacturing process of Chymotrypsin active pharmaceutical ingredient (API) in detail. Different forms of Chymotrypsin DMFs exist exist since differing nations have different regulations, such as Chymotrypsin USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Chymotrypsin DMF submitted to regulatory agencies in the US is known as a USDMF. Chymotrypsin USDMF includes data on Chymotrypsin's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Chymotrypsin USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Chymotrypsin suppliers with USDMF on PharmaCompass.
A Chymotrypsin CEP of the European Pharmacopoeia monograph is often referred to as a Chymotrypsin Certificate of Suitability (COS). The purpose of a Chymotrypsin CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Chymotrypsin EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Chymotrypsin to their clients by showing that a Chymotrypsin CEP has been issued for it. The manufacturer submits a Chymotrypsin CEP (COS) as part of the market authorization procedure, and it takes on the role of a Chymotrypsin CEP holder for the record. Additionally, the data presented in the Chymotrypsin CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Chymotrypsin DMF.
A Chymotrypsin CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Chymotrypsin CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Chymotrypsin suppliers with CEP (COS) on PharmaCompass.
Chymotrypsin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Chymotrypsin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Chymotrypsin GMP manufacturer or Chymotrypsin GMP API supplier for your needs.
A Chymotrypsin CoA (Certificate of Analysis) is a formal document that attests to Chymotrypsin's compliance with Chymotrypsin specifications and serves as a tool for batch-level quality control.
Chymotrypsin CoA mostly includes findings from lab analyses of a specific batch. For each Chymotrypsin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Chymotrypsin may be tested according to a variety of international standards, such as European Pharmacopoeia (Chymotrypsin EP), Chymotrypsin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Chymotrypsin USP).
LOOKING FOR A SUPPLIER?